~3 spots leftby Jul 2025

Dietary Fiber for Short Bowel Syndrome

LA
CB
Overseen byChristina Bales, MD
Age: < 65
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: Children's Hospital of Philadelphia
Disqualifiers: Intestinal diseases, Ileostomy, Jejunostomy, others
No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial tests if adding dietary fiber to liquid nutrition helps children with short bowel syndrome (SBS) absorb nutrients better. Researchers will monitor symptoms and gut health to see if the fiber is well-tolerated. The goal is to find out if fiber can improve their condition without causing side effects.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you must be on a stable antibiotic regimen starting from 2 weeks before the study and throughout the study period.

What data supports the effectiveness of the treatment Green bean puree for Short Bowel Syndrome?

Research suggests that adding fiber to enteral feedings can help manage increased stool output in short bowel syndrome, although there are no standardized guidelines. Blenderized feeds, which include whole food components like green beans, are becoming popular for enteral nutrition, but evidence is still limited.12345

Is dietary fiber from beans safe for humans?

Research suggests that beans, which are high in dietary fiber, are generally safe and may even offer health benefits like reducing cancer risk and inflammation. However, specific safety data for green bean puree or similar preparations in humans with short bowel syndrome is limited.16789

How does green bean puree treatment for short bowel syndrome differ from other treatments?

Green bean puree is unique because it provides a natural source of dietary fiber, which can help improve gut health and function. Unlike other treatments that may involve medications or supplements, this approach uses a whole food that is rich in both soluble and insoluble fibers, potentially benefiting digestion and nutrient absorption in a more holistic way.710111213

Research Team

LA

Lindsey Albenberg, DO

Principal Investigator

Children's Hospital of Philadelphia

CB

Christina Bales, MD

Principal Investigator

Children's Hospital of Philadelphia

WZ

Wenjing Zong, MD

Principal Investigator

Children's Hospital of Philadelphia

Eligibility Criteria

This trial is for children with Short Bowel Syndrome (SBS) who get most of their nutrition through special formulas without fiber, and a control group without intestinal issues. Participants should be stable on antibiotics if used, and SBS patients must have had part of their bowel removed but still connected to some colon.

Inclusion Criteria

Actively follows at the Children's Hospital of Philadelphia (CHOP) outpatient clinics
I have been on a stable antibiotic regimen for at least 2 weeks.
I have a history of short bowel syndrome, had part of my intestine removed, and still have some of my colon connected.
See 7 more

Exclusion Criteria

My small bowel and colon are not connected due to a stoma.
>5% changes in percentage of calories from oral nutrition, enteral nutrition, and/or parenteral nutrition during the intervention
I have never been diagnosed with Short Bowel Syndrome and have not had surgery to remove part of my intestine.
See 3 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive green bean purees added to enteral formula recipes over 3 weeks, with increasing amounts each week.

3 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment, including assessment of GI symptoms and microbiome/metabolome changes.

3 weeks-6 months

Treatment Details

Interventions

  • Green bean puree (Dietary Supplement)
Trial OverviewThe study tests how green bean puree affects kids with SBS compared to healthy controls. It looks at gastrointestinal symptoms, changes in gut bacteria, and metabolites to see if dietary fiber is tolerated differently between the two groups.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Short Bowel Syndrome ArmExperimental Treatment1 Intervention
Patients with SBS will be initiated on green bean purees added to enteral formula recipes, based on kilocalories of enteral formula over 3 weeks. During week 1 subjects will prepare and add 50 mL green bean puree per 1000kcal of enteral feed (5%) to their formula mixture, increasing to 100ml (10%) and 150ml (15%) during weeks 2 and 3, respectively.
Group II: Control Arm -Active Control1 Intervention
Patients without SBS will be initiated on green bean purees added to enteral formula recipes, based on kilocalories of enteral formula over 3 weeks. During week 1 subjects will prepare and add 50 mL green bean puree per 1000kcal of enteral feed (5%) to their formula mixture, increasing to 100ml (10%) and 150ml (15%) during weeks 2 and 3, respectively.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Children's Hospital of Philadelphia

Lead Sponsor

Trials
749
Recruited
11,400,000+
Joseph W. St. Geme III profile image

Joseph W. St. Geme III

Children's Hospital of Philadelphia

Chief Medical Officer since 2021

MD, PhD, MPH

Madeline Bell profile image

Madeline Bell

Children's Hospital of Philadelphia

Chief Executive Officer since 2015

BSc in Nursing from Villanova University, MSc in Organizational Dynamics from the University of Pennsylvania

University of Pennsylvania

Collaborator

Trials
2,118
Recruited
45,270,000+
Dr. Joan Lau profile image

Dr. Joan Lau

University of Pennsylvania

Chief Executive Officer since 2020

PhD in Neuroscience from the University of Cincinnati College of Medicine, MBA from the Wharton School of Business, BS in Bioengineering from the University of Pennsylvania

Dr. Robert Iannone profile image

Dr. Robert Iannone

University of Pennsylvania

Chief Medical Officer since 2019

MD from Yale University, MSCE from the University of Pennsylvania

Findings from Research

In a study of 58 pediatric patients with short bowel syndrome (SBS), those who received blenderized feeds showed improved gastrointestinal symptoms, particularly reduced diarrhea, although they experienced increased gas.
Patients with colonic resection were more likely to discontinue blenderized feeds, and a subgroup of patients who lost weight despite improved diarrhea often had a history of ileocecal valve and colonic resection, suggesting that careful management and titration of these feeds may be necessary for optimal outcomes.
Blenderized enteral nutrition in pediatric short gut syndrome: Tolerance and clinical outcomes.Zong, W., Troutt, R., Merves, J.[2023]
A survey of 94 healthcare professionals revealed that pectin is the most commonly used fiber supplement for managing chronic high stool output in pediatric short bowel syndrome (SBS).
Key factors influencing the initiation and discontinuation of fiber therapy include stool consistency and volume, with many providers discontinuing treatment within 2 weeks if no improvement is observed, particularly due to abdominal distention.
Soluble Fiber Use in Pediatric Short Bowel Syndrome: A Survey on Prevailing Practices.Harvie, ML., Norris, MAT., Sevilla, WMA.[2018]
Cholylsarcosine significantly improved fat absorption in short bowel syndrome patients, increasing daily fat absorption by 44% and providing an additional 261 kcal/day, while also allowing three patients to gain weight without worsening diarrhea.
In contrast, natural conjugated bile acids reduced steatorrhea but led to a significant increase in diarrhea, indicating that cholylsarcosine is a safer and more effective option for enhancing nutritional status in these patients.
Conjugated bile acid replacement therapy in short bowel syndrome patients with a residual colon.Kapral, C., Wewalka, F., Praxmarer, V., et al.[2017]

References

Blenderized enteral nutrition in pediatric short gut syndrome: Tolerance and clinical outcomes. [2023]
Soluble Fiber Use in Pediatric Short Bowel Syndrome: A Survey on Prevailing Practices. [2018]
Conjugated bile acid replacement therapy in short bowel syndrome patients with a residual colon. [2017]
Triple tube therapy: a novel enteral feeding technique for short bowel syndrome in low-income countries. [2007]
[Short bowel: from resection to transplantation]. [2016]
Dietary cooked navy beans and their fractions attenuate colon carcinogenesis in azoxymethane-induced ob/ob mice. [2021]
Genetic Architecture of Dietary Fiber and Oligosaccharide Content in a Middle American Panel of Edible Dry Bean. [2018]
Cooked navy and black bean diets improve biomarkers of colon health and reduce inflammation during colitis. [2020]
Common Beans and Their Non-Digestible Fraction: Cancer Inhibitory Activity-An Overview. [2020]
10.United Statespubmed.ncbi.nlm.nih.gov
Adaptation of the AOAC 2011.25 integrated total dietary fiber assay to determine the dietary fiber and oligosaccharide content of dry edible beans. [2017]
11.United Statespubmed.ncbi.nlm.nih.gov
Influence of frequent and long-term bean consumption on colonic function and fermentation. [2018]
Effects of Whole Brown Bean and Its Isolated Fiber Fraction on Plasma Lipid Profile, Atherosclerosis, Gut Microbiota, and Microbiota-Dependent Metabolites in Apoe-/- Mice. [2022]
Dry Bean: A Protein-Rich Superfood With Carbohydrate Characteristics That Can Close the Dietary Fiber Gap. [2023]